BioCentury
ARTICLE | Product Development

Cortech Adopts Apache lll

July 6, 1993 7:00 AM UTC

Cortech Inc. has become the second company to adopt the Apache III data base to derive a risk model for patients enrolling in sepsis trials.

CRTQ filed with the FDA a revised analysis plan for its 500-patient Phase II study of Bradycor bradykinin antagonist. The company will use APACHE III to assign a risk score to each patient entering the trial, allowing CRTQ to compare patients at the same risk level in the treatment and control groups. "Two things affect patient outcomes: risk and drug/no drug," said Timothy Rodell, senior vice president of operations and product development. "This allows you to subtract out risk to see the drug's effect."...